119 related articles for article (PubMed ID: 6811167)
1. Intranasal LHRH agonist treatment for inhibition of ovulation in women: clinical aspects.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Jul; 17(1):91-8. PubMed ID: 6811167
[TBL] [Abstract][Full Text] [Related]
2. Intranasal gonadotropin-releasing hormone agonist as a contraceptive agent.
Bergquist C; Nillius SJ; Wide L
Lancet; 1979 Aug; 2(8136):215-7. PubMed ID: 89330
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist.
Bergquist C; Nillius SJ; Wide L
Contraception; 1979 May; 19(5):497-506. PubMed ID: 380892
[TBL] [Abstract][Full Text] [Related]
4. Endometrial patterns in women on chronic luteinizing hormone-releasing hormone agonist treatment for contraception.
Bergquist C; Nillius SJ; Wide L; Lindgren A
Fertil Steril; 1981 Sep; 36(3):339-42. PubMed ID: 6793403
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment with the gonadotropin-releasing hormone agonist D-Ser(TBU)6-EA10-LRH for contraception in women and men.
Nillius SJ; Bergquist C; Wide L
Int J Fertil; 1980; 25(3):239-46. PubMed ID: 6108935
[TBL] [Abstract][Full Text] [Related]
6. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
Lemay A; Faure N
J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
[TBL] [Abstract][Full Text] [Related]
7. Peptide contraception in women. Inhibition of ovulation by chronic intranasal LRH agonist therapy.
Bergquist C; Nillius SJ; Wide L
Ups J Med Sci; 1984; 89(2):99-106. PubMed ID: 6431676
[TBL] [Abstract][Full Text] [Related]
8. Failure of positive feedback of oestradiol during chronic intranasal luteinizing hormone-releasing hormone agonist treatment.
Bergquist C; Nillius SJ; Wide L
Clin Endocrinol (Oxf); 1982 Feb; 16(2):147-51. PubMed ID: 6802530
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
10. Early follicular phase luteinizing hormone-releasing hormone agonist administration - effects on follicular maturation and corpus luteum function in women.
Skarin G; Nillius SJ; Wide L
Contraception; 1982 Jan; 25(1):31-9. PubMed ID: 6800690
[TBL] [Abstract][Full Text] [Related]
11. Luteolytic activity of LHRH and [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide: a new and physiological approach to contraception in women.
Lemay A; Labrie F; Raynaud JP
Int J Fertil; 1980; 25(3):203-12. PubMed ID: 6108931
[TBL] [Abstract][Full Text] [Related]
12. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
Kuhl H; Jung C; Taubert HD
Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
[TBL] [Abstract][Full Text] [Related]
13. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
[TBL] [Abstract][Full Text] [Related]
14. Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women.
Lemay A; Faure N; Labrie F
Fertil Steril; 1982 Feb; 37(2):193-200. PubMed ID: 6800846
[TBL] [Abstract][Full Text] [Related]
15. Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Bergquist C; Nillius SJ; Wide L
Fertil Steril; 1982 Aug; 38(2):190-3. PubMed ID: 6809500
[TBL] [Abstract][Full Text] [Related]
16. Effects of a luteinizing hormone-releasing hormone agonist on luteal function in women.
Bergquist C; Nillius SJ; Wide L
Contraception; 1980 Sep; 22(3):287-93. PubMed ID: 7002443
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of ovulation by intranasal nafarelin, a new superactive agonist of GnRH.
Gudmundsson JA; Nillius SJ; Bergquist C
Contraception; 1984 Aug; 30(2):107-14. PubMed ID: 6238805
[TBL] [Abstract][Full Text] [Related]
18. Intranasal peptide contraception by inhibition of ovulation with the gonadotropin-releasing hormone superagonist nafarelin: six months' clinical results.
Gudmundsson JA; Nillius SJ; Bergquist C
Fertil Steril; 1986 May; 45(5):617-23. PubMed ID: 2938984
[TBL] [Abstract][Full Text] [Related]
19. Gonadotropin releasing hormone analogs for female contraception by inhibition of ovulation.
Nillius SJ
J Steroid Biochem; 1985 Nov; 23(5B):849-54. PubMed ID: 2934581
[TBL] [Abstract][Full Text] [Related]
20. Influence of the LH-RH analogue buserelin on cyclic ovarian function and on endometrium. A new approach to fertility control?
Schmidt-Gollwitzer M; Hardt W; Schmidt-Gollwitzer K; von der Ohe M; Nevinny-Stickel J
Contraception; 1981 Feb; 23(2):187-95. PubMed ID: 6786826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
